Autoimmune disorder drug delivery devices market to grow at a significant CAGR of 15.25% during 2020-2030. BIS Research provides deep market insight, industry analysis, trends & forecast 2030 that will help your business to grow.

The global market for autoimmune disorder drug delivery devices is expected to increase fivefold over the next decade. By 2030 the market is expected to be valued at 10.7 billion U.S. dollars. As of 2019, the market was valued at some 2.2 billion U.S. dollars.

Autoimmune Disorder Drug Delivery Devices Market is projected to grow at a CAGR of around 16.89% from 2022-27.

The global market for autoimmune disorder drug delivery devices is expected to increase fivefold over the next decade. It is also projected that outsourced manufacturing of these devices will increase from 21 to 28 percent over this period.

Check out Market Research Intellect's Autoimmune Disorder Drug Delivery Device Market Report, valued at USD 8.5 billion in 2024, with a projected growth to USD 15.2 billion by 2033 at a CAGR of 8.2% (2026-2033).

Check out Market Research Intellect's Autoimmune Disorder Drug Delivery Devices Market Report, valued at USD 5.2 billion in 2024, with a projected growth to USD 9.8 billion by 2033 at a CAGR of 8.4% (2026-2033).

The global autoimmune disorder drug delivery device market is experiencing robust growth, driven by the increasing prevalence of autoimmune diseases and the rising demand for convenient and effective drug administration methods. The market, estimated at $5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $9 billion by 2033. Several factors contribute to this expansion, including the development of innovative drug delivery systems like pre-filled syringes, autoinjectors, and wearable patches, offering improved patient compliance and reduced injection-related discomfort. Furthermore, the growing preference for home-based therapies and the increasing geriatric population, which is more susceptible to autoimmune disorders, significantly boosts market demand. Major pharmaceutical companies such as AbbVie, Amgen, Roche, and Novartis are actively investing in research and development to enhance drug delivery technologies, further fueling market expansion. The market segmentation is diverse, encompassing various device types (pre-filled syringes, autoinjectors, pens, patches), drug types (biologics, small molecules), and therapeutic areas (rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease). Geographic growth varies, with North America and Europe currently dominating the market due to high healthcare expenditure and advanced healthcare infrastructure. However, emerging economies in Asia-Pacific and Latin America are expected to exhibit significant growth potential in the coming years, driven by increasing healthcare awareness and rising disposable incomes. Despite the positive outlook, challenges like stringent regulatory approvals, high development costs, and potential side effects associated with certain delivery methods may somewhat restrain market growth. However, ongoing innovations and improvements in safety and efficacy profiles are likely to mitigate these challenges.

Global Autoimmune Disorder Drugs Delivery Device market size 2025 was XX Million. Autoimmune Disorder Drugs Delivery Device Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

The global market for autoimmune disorder drug delivery devices is experiencing robust growth, driven by the rising prevalence of autoimmune diseases, an aging population, and the increasing demand for convenient and effective drug administration methods. The market, estimated at $15 billion in 2025, is projected to exhibit a compound annual growth rate (CAGR) of 5%, reaching approximately $22 billion by 2033. This growth is fueled by several key factors. Firstly, the development of novel biologics and complex therapies for autoimmune disorders requires sophisticated delivery systems, stimulating innovation in this sector. Secondly, the preference for self-administered therapies, particularly among patients managing chronic conditions, drives the adoption of convenient devices like pen injectors and auto-injectors. Finally, advancements in device technology, such as improved usability, reduced pain during injection, and enhanced safety features, contribute to market expansion. Significant regional variations exist. North America currently holds a dominant market share due to high healthcare expenditure, advanced medical infrastructure, and a substantial patient population. However, emerging markets in Asia-Pacific, particularly China and India, are expected to witness rapid growth due to increasing awareness of autoimmune diseases, rising disposable incomes, and expanding healthcare access. The market is segmented by device type (pen injectors, auto-injectors, pre-filled syringes, vials) and application (hospital, clinic). Pen injectors and auto-injectors are currently leading segments due to their ease of use and portability. The competitive landscape is highly fragmented, with numerous established players like BD, Gerresheimer, and Schott competing alongside smaller specialized companies. Ongoing technological advancements, strategic partnerships, and product diversification strategies are expected to shape the future of this dynamic market.

Autoimmune Disorder Drug Delivery Device Market size was valued at USD 7.7 Bln (billion) in 2025 and the revenue is expected to grow at a CAGR of 7.9% from 2025 to 2032

The Global Injectable Drug Delivery Devices Market Size Was Worth USD 468 Billion in 2023 and Is Expected To Reach USD 577 Billion by 2032, CAGR of 6.7%.

Connected Injectable Drug Delivery Devices Market Outlook

The global connected injectable drug delivery devices market is poised for substantial growth, with market size expected to surge from USD 1.5 billion in 2023 to an estimated USD 3.8 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 10.7% during the forecast period. The growth of this market is driven by a confluence of factors, including technological advancements in drug delivery systems, an increasing prevalence of chronic diseases, and rising demand for home healthcare solutions. These devices, which integrate digital connectivity to improve medication adherence and patient outcomes, are revolutionizing the drug delivery landscape, making them an integral component of modern medical care.

One of the primary growth factors for the connected injectable drug delivery devices market is the escalating prevalence of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune diseases. With millions of individuals worldwide affected by these conditions, there is a growing need for efficient, reliable, and user-friendly drug delivery systems. Connected devices not only provide precise drug delivery but also enable real-time monitoring of patient compliance, thereby improving therapeutic outcomes. Moreover, the aging global population, which is more susceptible to chronic illnesses, further accentuates the demand for advanced drug delivery solutions, thus propelling the market growth.

Another significant growth driver is the technological innovations in connectivity solutions, such as Bluetooth, Wi-Fi, and Near Field Communication (NFC), which enhance the functionality and utility of injectable devices. These technologies facilitate seamless communication between the device and healthcare providers, allowing for remote monitoring and timely interventions. This capability is particularly beneficial in home care settings, where patients manage their treatments independently. The integration of artificial intelligence and machine learning algorithms into these devices has further enhanced their predictive analytics capabilities, enabling healthcare providers to tailor treatment plans based on comprehensive patient data.

The increasing adoption of home healthcare solutions is also contributing to the expansion of the connected injectable drug delivery devices market. As healthcare systems worldwide face pressure to reduce costs and improve efficiency, there is a shift towards decentralized care models that empower patients to manage their health at home. Connected devices offer a convenient and effective solution for home-based treatment, reducing the need for frequent hospital visits and lowering healthcare expenses. The COVID-19 pandemic has accelerated this trend, highlighting the importance of remote healthcare solutions and solidifying the role of connected devices in future healthcare delivery models.

Regionally, the market is witnessing varied growth trends, with North America and Europe accounting for significant shares due to their well-established healthcare infrastructures and high adoption rates of advanced medical technologies. The Asia Pacific region, however, is expected to witness the highest growth rate, driven by increasing healthcare investments, a burgeoning middle-class population, and a rising incidence of chronic diseases. Government initiatives aimed at improving healthcare access and quality further bolster market growth in this region, creating new opportunities for market players to expand their footprint.

Product Type Analysis

In the realm of connected injectable drug delivery devices, product type plays a crucial role in defining market dynamics, with smart syringes, smart wearable injectors, and smart insulin pens emerging as key segments. Smart syringes, equipped with advanced connectivity features, have revolutionized traditional drug administration methods by enhancing precision and reducing the risk of needle-stick injuries. These devices are particularly favored in clinical settings where accuracy and safety are paramount. The growing emphasis on patient safety protocols and the prevention of transmission-related risks in healthcare facilities are driving the demand for these innovative syringes.

Smart wearable injectors represent another vital segment, offering a convenient alternative for patients requiring regular and long-term medication administration, such as in cases of chronic diseases like diabetes and autoimmune disorders. These devices, designed to be worn on the body, facilitate continuous monitoring and automatic delivery of dru

The China drug delivery devices market, valued at an estimated $XX million in 2025, is poised for robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 9.21% from 2025 to 2033. This expansion is driven by several key factors. The rising prevalence of chronic diseases like cardiovascular ailments, cancer, and autoimmune disorders fuels demand for effective drug delivery systems. Technological advancements, particularly in areas like self-injectable devices (auto-injectors, pre-filled syringes) and implantable devices, are enhancing patient convenience and treatment efficacy, thereby driving market growth. Furthermore, the increasing focus on personalized medicine and the development of targeted therapies necessitate sophisticated drug delivery mechanisms. Government initiatives to improve healthcare infrastructure and enhance access to advanced medical technologies in China also contribute positively to market expansion. The market is segmented by device type (nasal inhalers, implantable, injectables), therapeutic application (cardiovascular, oncology, autoimmune, pulmonary), and sales channel (hospitals, pharmacies). While the market faces challenges such as stringent regulatory approvals and high research and development costs, the overall outlook remains positive, propelled by a growing geriatric population and increasing healthcare expenditure in China. The market's segmentation reveals significant opportunities across different therapeutic areas. Injectable drug delivery systems, particularly self-injectable devices, are experiencing rapid growth due to patient preference for home-based administration. The oncology segment holds substantial potential, driven by the rising incidence of various cancers and the need for targeted drug delivery. Hospitals remain a dominant sales channel, yet the expansion of pharmacy-based sales reflects the growing accessibility of drug delivery devices. Key players like Gerresheimer AG, Pfizer Inc., and Becton Dickinson are actively investing in research and development, expanding their product portfolios, and strengthening their market presence through strategic partnerships and collaborations. The competitive landscape is characterized by both established multinational corporations and emerging domestic players, leading to innovation and market diversification. Despite potential challenges from economic fluctuations or global health crises, the long-term growth trajectory of the China drug delivery devices market remains promising, driven by fundamental healthcare trends and technological advancements. Recent developments include: May 2024: Iconovo AB received approval from the Chinese Patent Office for a patent for the inhalation platform ICOres. With this, Iconovo is expected to receive patent protection for the inhaler in China until 2040 after a series of administrative steps., April 2024: Aptar Pharma received approval from the National Medical Products Administration (NMPA) in China for Sinomune Pharmaceutical’s Li Fu metronidazole gel. This drug is used to treat papulopustular rosacea, and Aptar Pharma’s Mezzo+ CS Airless dispensing solution is used for dermal drug delivery.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases, Advancement in Technology. Potential restraints include: Increasing Prevalence of Chronic Diseases, Advancement in Technology. Notable trends are: The Autoinjectors Segment is Expected to Hold Significant Market Share Over the Forecast Period.

USA Drug Delivery Devices Market size was valued at USD 22.6 Billion in 2024 and is projected to reach USD 45.2 Billion by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.

USA Drug Delivery Devices Market Drivers

Rising Prevalence of Chronic Diseases: Chronic conditions like diabetes, cancer, and respiratory diseases are on the rise in the USA. These diseases require long-term drug therapies, driving the demand for efficient drug delivery devices such as insulin pens, nebulizers, and auto-injectors. According to the CDC, about 6 in 10 adults in the USA have at least one chronic disease, underscoring the need for advanced drug delivery solutions.

Advancements in Technology: Technological advancements, including smart drug delivery systems, are a significant driver. Devices equipped with IoT capabilities and real-time monitoring features are enhancing drug efficacy and patient adherence. Innovations like microneedle patches and implantable drug delivery systems are gaining traction.

Increasing Focus on Biologics: The growth of biologics and biosimilars, which require specialized delivery systems due to their molecular complexity, is propelling the market. Prefilled syringes and auto-injectors designed for biologic drugs are becoming increasingly popular.

Subcutaneous Drug Delivery Devices Market Outlook

The global subcutaneous drug delivery devices market size is projected to grow from USD 30.5 billion in 2023 to USD 58.2 billion by 2032, at a compound annual growth rate (CAGR) of 7.4% during the forecast period. This robust growth can be attributed to the rising prevalence of chronic diseases, advancements in drug delivery technologies, and the increasing demand for minimally invasive treatment options.

One of the primary growth factors driving the subcutaneous drug delivery devices market is the rising incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders. With the global burden of these diseases increasing, there is a growing need for efficient and effective drug delivery systems that can improve patient compliance and outcomes. Subcutaneous drug delivery devices offer a convenient and less invasive alternative to traditional intravenous or oral drug administration, making them highly attractive for both patients and healthcare providers.

Technological advancements in drug delivery systems have significantly enhanced the capabilities and reliability of subcutaneous drug delivery devices. Innovations such as prefilled syringes, autoinjectors, and wearable injectors have revolutionized the way medications are administered, providing precise dosing, ease of use, and improved safety profiles. These advancements have not only increased the adoption of subcutaneous drug delivery devices but have also expanded their applications across various therapeutic areas, further driving market growth.

Moreover, the increasing preference for home healthcare and self-administration of medications is contributing to the growth of the subcutaneous drug delivery devices market. With the rising costs of hospital care and the convenience of self-administration, patients and caregivers are increasingly opting for devices that allow for easy and safe drug administration at home. This trend is supported by the availability of user-friendly and portable subcutaneous drug delivery devices, which empower patients to manage their conditions effectively and independently.

Pharmaceutical Drug Delivery Devices are pivotal in the realm of subcutaneous drug delivery, offering innovative solutions that enhance the precision and efficiency of medication administration. These devices are designed to deliver drugs directly into the subcutaneous tissue, ensuring rapid absorption and prolonged therapeutic effects. With the increasing complexity of biologic drugs and the need for targeted delivery, pharmaceutical drug delivery devices are becoming essential tools in modern healthcare. They not only improve patient compliance by simplifying the administration process but also reduce the potential for dosing errors, thereby enhancing patient safety. As the demand for personalized medicine grows, the role of pharmaceutical drug delivery devices in tailoring treatment regimens to individual patient needs is becoming increasingly significant.

Regionally, North America holds the largest share of the subcutaneous drug delivery devices market, driven by the high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investments in research and development. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to the increasing awareness of subcutaneous drug delivery devices, improving healthcare facilities, and rising healthcare expenditure in emerging economies such as China and India.

Product Type Analysis

The subcutaneous drug delivery devices market is segmented into various product types, including prefilled syringes, autoinjectors, wearable injectors, and others. Prefilled syringes are one of the most widely used devices in this market segment, due to their convenience, accuracy in dosing, and reduced risk of contamination. The increasing adoption of biologic drugs, which are often administered via prefilled syringes, is also boosting the growth of this segment. Additionally, advancements in syringe technology, such as improved needle designs and materials, have enhanced patient comfort and increased the overall acceptance of prefilled syringes.

Autoinjectors are another significant segment within the subcutaneous drug delivery devices market. These devices are designed to simplify the self-administration of injectable medications, making them particularly useful fo

Injectable Drug Delivery Devices Market Outlook

According to our latest research, the global injectable drug delivery devices market size reached USD 42.8 billion in 2024, demonstrating robust growth driven by rising prevalence of chronic diseases and technological advancements in drug delivery systems. The market is expected to expand at a CAGR of 8.2% from 2025 to 2033, reaching a value of approximately USD 85.6 billion by 2033. The surge in patient preference for self-administration, coupled with the growing demand for minimally invasive treatment options, is a major factor fueling this market’s expansion as per our latest research findings.

One of the primary growth drivers of the injectable drug delivery devices market is the increasing global burden of chronic diseases, such as diabetes, cancer, and autoimmune disorders. With the World Health Organization estimating that non-communicable diseases account for over 70% of deaths worldwide, the need for efficient and reliable drug delivery methods has become paramount. Injectable devices, such as prefilled syringes, auto-injectors, and pen injectors, offer precise dosing and improved patient compliance, especially for long-term therapies. The continuous rise in the diabetic population, particularly in emerging economies, has significantly contributed to the adoption of self-injectable devices, making them an integral part of modern healthcare infrastructure.

Technological innovation has played a crucial role in shaping the injectable drug delivery devices market. Companies are investing heavily in research and development to introduce smart, connected, and wearable injectors that enhance patient convenience and safety. The evolution of biologics and biosimilars, which often require parenteral administration, has further accelerated the demand for advanced injectable devices. Features such as dose memory, connectivity for remote monitoring, and ergonomic designs are now increasingly integrated into these devices, catering to both healthcare professionals and patients. Additionally, the rising trend of home healthcare and the shift towards outpatient care settings have spurred the development of user-friendly, self-administration devices, broadening the market’s reach.

Another significant factor propelling the market is the growing emphasis on patient-centric care and the reduction of healthcare costs. Injectable drug delivery devices facilitate self-management of chronic conditions, thereby reducing the frequency of hospital visits and associated expenses. Health systems across developed and developing regions are recognizing the value of these devices in improving therapeutic outcomes and enhancing quality of life for patients. Moreover, favorable reimbursement policies and regulatory support for innovative drug-device combinations have encouraged manufacturers to expand their product portfolios. As healthcare providers and payers increasingly prioritize cost-effective and efficient treatment modalities, the injectable drug delivery devices market is poised for sustained growth.

Regionally, North America continues to dominate the injectable drug delivery devices market, accounting for the largest revenue share in 2024, followed closely by Europe and the Asia Pacific. The high prevalence of chronic diseases, strong healthcare infrastructure, and early adoption of advanced medical technologies are key factors supporting North America’s leadership. However, the Asia Pacific region is emerging as the fastest-growing market segment, driven by increasing healthcare expenditure, large patient populations, and rising awareness about self-injectable therapies. Latin America and the Middle East & Africa are also witnessing steady growth, albeit at a slower pace, due to improving access to healthcare services and expanding pharmaceutical distribution networks.

Product Type Analysis

The injectable drug delivery devices market is segmented by product type into self-injectors, auto-inject

The Subcutaneous Drug Delivery Devices Market size was valued at USD 23.3 billion in 2023 and is projected to reach USD 46.57 billion by 2032, exhibiting a CAGR of 10.4 % during the forecasts period. It refers to the devices intended to deliver a medicine completely through the skin layers, especially by injections or an infusion process. These Devices help in controlled and extended release of drugs which has its benefits such as better compliance by the patients & less frequent administration and accurate delivery of Biologics, Insulin, hormones and vaccines. Some of the medical conditions it is used to treat:; diabetes, autoimmune diseases, hormonal disorders, and pain; and in cases of emergencies. Market trends are underway with we-wearable and smart devices for long-term telemetric and administered drug delivery, biocompatibility period trends and integration of digital technologies for optimized dosing schedules. The key factors stimulating growth are the growth of the incidence of chronic diseases, the increased demand for less invasive treatments, and developments in upgrading treatment options in terms of patients’ comfort and treatment effects.

• The global industry was valued at US$ 390.7 Mn in 2023
• It is expected to grow at a CAGR of 6.8% from 2024 to 2034 and reach US$ 796.1 Mn by the end of 2034

On-body Drug Delivery Devices Market Overview

Regional Analysis of On-body Drug Delivery Devices Market

On-body Drug Delivery Devices Market Snapshot

The global injectable drug delivery devices market is projected to grow from $114.85 billion in 2025 to $209.85 billion by 2033, at a CAGR of 7.14% from 2025 to 2033. The growth of this market can be attributed to the increasing prevalence of chronic diseases requiring injectable therapies, such as diabetes and autoimmune disorders. Additionally, the advancements in drug delivery technologies, such as the development of prefilled syringes and auto-injectors, are expected to further drive the market growth. The market is segmented based on device type, therapeutic application, and region. Based on device type, the conventional drug delivery devices segment is expected to hold the largest market share during the forecast period, owing to the widespread use of these devices for the delivery of traditional injectable medications. However, the advanced drug delivery devices segment is projected to witness the highest CAGR from 2025 to 2033, due to the increasing adoption of these devices for the delivery of complex drugs, such as biologics and targeted therapies. Geographically, North America is expected to dominate the injectable drug delivery devices market over the forecast period, followed by Europe and Asia Pacific. Recent developments include: November 2022: Medmix Drug Delivery (Haselmeier) and AARDEX Group collaborated by combining Haselmeiers D-Flex Logbook with AARDEX Group's Medication Adherence software and Hardware ecosystem to improve self-administration of injectable drugs in clinical trials in Germany., January 2022: Hikma Pharmaceuticals USA Inc., a subsidiary of Hikma Pharmaceuticals, launched Diazepam Injection, USP. The company introduced a 5mg/mL dosage in a 2mL dose, and with this launch, Hikma has now released its second drug in the form of a prefilled syringe.. Key drivers for this market are: Increasing Burden of Chronic Diseases, Benefits and Convenience in Self Injectors; Growth of the Biologics Market Leading to Increased Demand for Injectors. Potential restraints include: Injuries and Infections Caused by Needles, Increasing Use of Alternative Delivery Methods. Notable trends are: Prefilled Syringes Subsegment is Anticipated to Grow Significantly Over the Forecast Period.

The size of the Injectable Drug Delivery Devices Market was valued at USD 44.12 billion in 2024 and is projected to reach USD 90.45 billion by 2033, with an expected CAGR of 10.8% during the forecast period. The injectable drug delivery devices market is continuously influenced with the rising prevalence of chronic diseases like diabetes, cancer, autoimmune disorders and therefore advancements in biologics and biosimilars. Since injectable drug delivery systems are known to quickly absorb drugs and guarantee exact dosing, they also ensure improved compliance towards patients, particularly self-administered therapies. The major types of injectable drug delivery instruments include syringes, both conventional and prefilled, autoinjectors, pen injectors, and needle-free injectors. The applicability of these systems is both inside and outside the hospital infrastructure to support the treatment of varied conditions such as rheumatoid arthritis, multiple sclerosis, and disorders of hormonal origin. North America and Europe lead the market due to widespread adoption of advanced drug delivery technology, strong healthcare systems, and an increase in the biographies', in particular biopharmaceuticals investment. Towards the east, Asia is increasing rapidly due to mushrooming healthcare expenditure, expanding pharmaceutical manufacture, and the rise of self-administration devices. Some of the market restraints include high device costs, the need for tedious regulatory approvals, and incidences of needle-stick injuries. In the meantime, innovations in smart injectors, connected drug delivery devices, and patient-friendly designs are likely to promote growth. With increasing expansion of biologics and personalized medicine, advanced injectable drug delivery solutions will see extraordinary demand in the coming years.